FDA Approves Olutasidenib for Relapsed or Refractory AML with a Susceptible IDH1 Mutation

On December 1, 2022, the U.S Food and Drug Administration (FDA) approved olutasidenib capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. 

For more information read the FDA announcement and the Rigel announcement.

Posted 12/2/2022